Aclarubicin - CAS 57576-44-0
Not Intended for Therapeutic Use. For research use only.
Category:
Inhibitor
Product Name:
Aclarubicin
Catalog Number:
57576-44-0
Synonyms:
11-Dioxo-4-((2,3,6-trideoxy-4-o-(2,6-dideoxy-4-o-((2r-trans)-tetrahydro-6-met;1-naphthacenecarboxylicacid,2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6;(1R,2R,4S)-methyl 4-(((2R,5S,6S)-4-(dimethylamino)-5-(((2S,4S,5S,6S)-4-hydroxy-6-methyl-5-(((2R,6S)
CAS Number:
57576-44-0
Description:
Aclarubicin is an oligosaccharide anthracycline antineoplastic antibiotic isolated from the bacterium Streptomyces galilaeus. It intercalates into DNA and interacts with topoisomerases I and II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. It is antagonistic to other agents that inhibit topoisomerase II, such as etoposide, teniposide and amsacrine. It has potent antineoplastic activity. It is used in the treatment of cancer. It can induce histone eviction from chromatin upon intercalation. It has been listed.
Molecular Weight:
811.87
Molecular Formula:
C42H53NO15
Quantity:
Kilograms to Tons
Quality Standard:
In-house standard
COA:
Inquire
MSDS:
Inquire
Canonical SMILES:
CCC1(CC(C2=C(C1C(=O)OC)C=C3C(=C2O)C(=O)C4=C(C3=O)C=CC=C4O)OC5CC(C(C(O5)C)OC6CC(C(C(O6)C)OC7CCC(=O)C(O7)C)O)N(C)C)O
InChI:
InChI=1S/C42H53NO15/c1-8-42(51)17-28(33-22(35(42)41(50)52-7)14-23-34(38(33)49)37(48)32-21(36(23)47)10-9-11-26(32)45)56-30-15-24(43(5)6)39(19(3)54-30)58-31-16-27(46)40(20(4)55-31)57-29-13-12-25(44)18(2)53-29/h9-11,14,18-20,24,27-31,35,39-40,45-46,49,51H,8,
InChIKey:
USZYSDMBJDPRIF-SVEJIMAYSA-N
Targets:
Topoisomerase
Current Developer:
Aclarubicin has been listed.
Chemical Structure
CAS 57576-44-0 Aclarubicin

Related Topoisomerase Products


CAS 86639-52-3 SN-38

SN-38
(CAS: 86639-52-3)

SN-38 is the active metabolite of irinotecan. In vitro cytotoxicity assays show that the potency of SN-38 relative to irinotecan varies from 2- to 2000-fold. SN...

CAS 171335-80-1 Exatecan mesylate

Exatecan mesylate
(CAS: 171335-80-1)

Exatecan mesylate is a semisynthetic, water-soluble derivative of camptothecin with antineoplastic activity. Exatecan mesylate inhibits topoisomerase I activity...

ABT-719
(CAS: 162829-90-5)

ABT-719, a fluoroquinolone derivative, has been found to be a DNA topoisomerase inhibitor that was once developed in antibacterial studies.

CAS 57852-57-0 Idarubicin Hydrochloride

Idarubicin Hydrochloride
(CAS: 57852-57-0)

Idarubicin HCl is a hydrochloride salt form of Idarubicin which is an anthracycline antibiotic and a DNA topoisomerase II (topo II) inhibitor for MCF-7 cells wi...

CAS 119413-54-6 Topotecan Hydrochloride

Topotecan Hydrochloride
(CAS: 119413-54-6)

Topocecan is a semisynthetic derivative of camptothecin with antineoplastic activity. During the S phase of the cell cycle, topotecan selectively stabilizes top...

CAS 174634-09-4 TAS-103

TAS-103
(CAS: 174634-09-4)

TAS-103, also known as BMS-247615, is a quinoline derivative that displays antitumor activity in murine and human tumor models. TAS-103 has been reported to be ...

CAS 162706-37-8 Elinafide

Elinafide
(CAS: 162706-37-8)

Elinafide, an isoquinoline derivative, has been found to be a Type II DNA topoisomerase inhibitor that was once developed in anticancer studies.

CAS 136572-09-3 Irinotecan HydrochlorideTrihydrate

Irinotecan HydrochlorideTrihydrate
(CAS: 136572-09-3)

Irinotecan is activated to SN-38 by carboxylesterases to become able to interact with its target, topoisomerase I.

SW044248
(CAS: 522650-83-5)

SW044248 is a potent and selective Topoisomerase I inhibitor. SW044248 killed approximately 15% of a panel of 74 NSCLC cell lines and was nontoxic to immortaliz...

CP 117227
(CAS: 154531-78-9)

CP 117227, a dibenzocyclohepten derivative, has been found to be a Type II DNA topoisomerase inhibitor that was once developed in studies of anticancer.

CAS 78186-34-2 Bisantrene Dihydrochloride

Bisantrene Dihydrochloride
(CAS: 78186-34-2)

Bisantrene Dihydrochloride is the hydrochloride salt of Bisantrene. Bisantrene, also referred to CL-216942, Cyabin or NSC-337766, an anthracene bishydrazone der...

ABT-719 HCl
(CAS: 162763-53-3)

The hydrochloride salt form of ABT-719, a fluoroquinolone derivative, has been found to be a DNA topoisomerase inhibitor that was once developed in antibacteria...

Tilfrinib
(CAS: 1600515-49-8)

Tilfrinib, a pyridoindol derivative, has been found to be a breast tumor kinase (Brk) inhibitor that could probably restrain the proliferation of breast cancer ...

CAS 529488-28-6 GENZ-644282

GENZ-644282
(CAS: 529488-28-6)

Genz-644282 is a non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity. Topoisomerase I inhibitor Genz-644282 binds to and inhibi...

Alatrofloxacin Mesylate
(CAS: 157605-25-9)

The mesylate salt form of alatrofloxacin, a fluoroquinolone derivative, has been found to be a Type II DNA topoisomerase inhibitor that was once developed to be...

CAS 70476-82-3 Mitoxantrone HCl

Mitoxantrone HCl
(CAS: 70476-82-3)

Mitoxantrone is a type II topoisomerase inhibitor with IC50 of 2.0 μM, 0.42 mM for HepG2 and MCF-7/wt cells, respectively.

CAS 446-72-0 Genistein

Genistein
(CAS: 446-72-0)

Genistein, a phytoestrogen found in soy products, is a highly specific inhibitor of protein tyrosine kinase (PTK) which blocks the mitogenic effect mediated by ...

CAS 97682-44-5 Irinotecan

Irinotecan
(CAS: 97682-44-5)

Irinotecan is a topoisomerase I inhibitor for LoVo cells and HT-29 cells with IC50 of 15.8 μM and 5.17 μM, respectively.

CAS 74550-97-3 Bimolane

Bimolane
(CAS: 74550-97-3)

Bimolane is a topoisomerase II inhibitor. It has been widely used as an anti-neoplastic agent and for the treatment of psoriasis in China. Bimolane is also a le...

CAS 110311-30-3 Amrubicin hydrochloride

Amrubicin hydrochloride
(CAS: 110311-30-3)

Amrubicin hydrochloride is a topoisomerase II inhibitor used in the treatment of lung cancer.

Reference Reading


1.Generation of hydroxyl radical by anticancer quinone drugs, carbazilquinone, mitomycin C, aclacinomycin A and adriamycin, in the presence of NADPH-cytochrome P-450 reductase.
Komiyama T, Kikuchi T, Sugiura Y. Biochem Pharmacol. 1982 Nov 15;31(22):3651-6.
The generation of hydroxyl free radicals in the system consisting of purified NADPH-cytochrome P-450 reductase and anticancer quinone drugs, such as carbazilquinone, mitomycin C, aclacinomycin A and adriamycin, has been confirmed by two methods. In the spin trapping study, using N-tert-butyl-alpha-phenylnitrone as the spin trapping agent, four drugs generated hydroxyl radical-trapped signals, and the formation of the spin adduct was dependent on time and the enzyme concentration. Among the four drugs, the generation time of signal was in the order of carbazilquinone, aclacinomycin A, adriamycin and mitomycin C, but the magnitude of signal intensity was different. In both aclacinomycin A and adriamycin, the signal disappeared in a few minutes. Catalase completely inhibited the formation of the spin adduct, while superoxide dismutase did not significantly inhibit, but effected in some manner. The generation of hydroxyl radical was also confirmed by the ethylene production from methional.
2.Antitumor activity of mitoxantrone against murine experimental tumors: comparative analysis against various antitumor antibiotics.
Fujimoto S, Ogawa M. Cancer Chemother Pharmacol. 1982;8(2):157-62.
1,4-Dihydroxy-5,8-bis(((2-[(2-hydroxyethyl) amino] ethyl)amino))-9,10-anthracenedione dihydrochloride (mitoxantrone) was tested for antitumor activity against experimental tumors in mice and the results were compared with those of seven antitumor antibiotics: adriamycin (ADM), daunomycin (DM), aclarubicin, mitomycin C (MNC), bleomycin, neocarzinostatin, and chromomycin A3. The drugs were given IP or IV, in general on days 1, 5, and 9 following tumor inoculation. Mitoxantrone given IP at the optimal dose (1.6 mg/kg/day; as a free base) produced a statistically significant number of 60-day survivors (curative effect) in mice with IP implanted L1210 leukemia. The curative effect was not observed with any of the other antibiotics. In the case of IV implanted L1210 leukemia, there was an increase in lifespan (ILS) by more than 100% in the mice following IV treatment with mitoxantrone or DM. In IP implanted P388 leukemia, the curative effect was elicited by IP treatment with mitoxantrone or MMC.
3.Interactions of anticancer quinone drugs, aclacinomycin A, adriamycin, carbazilquinone, and mitomycin C, with NADPH-cytochrome P-450 reductase, xanthine oxidase and oxygen.
Komiyama T, Kikuchi T, Sugiura Y. J Pharmacobiodyn. 1986 Aug;9(8):651-64.
The properties of the interactions of anticancer quinone drugs, aclacinomycin A, adriamycin, carbazilquinone, and mitomycin C with nicotinamide adenine dinucleotide phosphate (NADPH)-cytochrome P-450 reductase and xanthine oxidase under anaerobic and aerobic conditions were studied. Km values of NADPH-cytochrome P-450 reductase for these drugs were in the range of 40-227 microM, and that of deflavo xanthine oxidase in the range of 39-over 200 microM. Under anaerobic conditions, when xanthine was used as an electron donor, deflavo xanthine oxidase catalyzed the reductive glycosidic cleavage reaction of anthracyclines and nicotinamide adenine dinucleotide was ineffective as an electron donor. In the electron spin resonance study, the formation of the semiquinone or free radical state of the quinone drugs in both enzyme systems were evidenced. A weak and symmetric signal was obtained from aclacinomycin A, and a symmetric signal from adriamycin was changed into an asymmetric and strong.
4.Thermodynamics of the anthracycline-nuclei interactions in drug-resistant and drug-sensitive K562 cells.
Tarasiuk J1, Garnier-Suillerot A. Biochem Pharmacol. 1992 Jun 23;43(12):2575-80.
Fluorescence emission spectra from anthracycline-treated cells suspended in buffer have been used to measure the uptake of three anthracycline derivatives: Adriamycin (ADR), 4'-o-tetrahydropyranyl-Adriamycin (THP-ADR) and aclacinomycin (ACM) in drug-sensitive and drug-resistant K562 cells. The concentration of drug bound to the nucleus and free in the cytoplasm, at steady state, as well as the concentration of drug bound to the nucleus at equilibrium state have been determined at temperatures ranging from 6 degrees to 40 degrees. The enthalpies for the binding of ADR, THP-ADR and ACM to nuclei equal -35 +/- 3, -35 +/- 3 and -30 +/- 3 kJ/mol, respectively. These values compare with the enthalpies of binding of these drugs to naked DNA.